146 related articles for article (PubMed ID: 32015321)
21. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
Chen W; Qiu J; Shen YM
Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
[TBL] [Abstract][Full Text] [Related]
22. SUMO-Targeted DNA Translocase Rrp2 Protects the Genome from Top2-Induced DNA Damage.
Wei Y; Diao LX; Lu S; Wang HT; Suo F; Dong MQ; Du LL
Mol Cell; 2017 Jun; 66(5):581-596.e6. PubMed ID: 28552615
[TBL] [Abstract][Full Text] [Related]
23. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
24. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
25. A protease pathway for the repair of topoisomerase II-DNA covalent complexes.
Zhang A; Lyu YL; Lin CP; Zhou N; Azarova AM; Wood LM; Liu LF
J Biol Chem; 2006 Nov; 281(47):35997-6003. PubMed ID: 16973621
[TBL] [Abstract][Full Text] [Related]
26. The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.
Bombarde O; Larminat F; Gomez D; Frit P; Racca C; Gomes B; Guilbaud N; Calsou P
Mol Cancer Ther; 2017 Oct; 16(10):2166-2177. PubMed ID: 28611105
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis.
Yang YC; Chou HY; Shen TL; Chang WJ; Tai PH; Li TK
Antioxid Redox Signal; 2013 Apr; 18(10):1129-40. PubMed ID: 22998676
[TBL] [Abstract][Full Text] [Related]
28. RAD54L2-mediated DNA damage avoidance pathway specifically preserves genome integrity in response to topoisomerase 2 poisons.
Zhang H; Xiong Y; Sun Y; Park JM; Su D; Feng X; Keast S; Tang M; Huang M; Wang C; Srivastava M; Yang C; Zhu D; Chen Z; Li S; Yin L; Pommier Y; Chen J
Sci Adv; 2023 Dec; 9(49):eadi6681. PubMed ID: 38055811
[TBL] [Abstract][Full Text] [Related]
29. FEN1 participates in repair of the 5'-phosphotyrosyl terminus of DNA single-strand breaks.
Kametani Y; Takahata C; Narita T; Tanaka K; Iwai S; Kuraoka I
Carcinogenesis; 2016 Jan; 37(1):56-62. PubMed ID: 26581212
[TBL] [Abstract][Full Text] [Related]
30. Putative E3 ubiquitin ligase of human rotavirus inhibits NF-κB activation by using molecular mimicry to target β-TrCP.
Morelli M; Dennis AF; Patton JT
mBio; 2015 Jan; 6(1):. PubMed ID: 25626907
[TBL] [Abstract][Full Text] [Related]
31. Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP2 poison anti-cancer drug etoposide.
Cowell IG; Austin CA
FEBS Open Bio; 2024 Mar; ():. PubMed ID: 38531625
[TBL] [Abstract][Full Text] [Related]
32. Functions of the CSB Protein at Topoisomerase 2 Inhibitors-Induced DNA Lesions.
Busatto FF; Mersaoui SY; Sun Y; Pommier Y; Masson JY; Saffi J
Front Cell Dev Biol; 2021; 9():727836. PubMed ID: 34746125
[TBL] [Abstract][Full Text] [Related]
33. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
34. Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in
Tombline G; Millen JI; Polevoda B; Rapaport M; Baxter B; Van Meter M; Gilbertson M; Madrey J; Piazza GA; Rasmussen L; Wennerberg K; White EL; Nitiss JL; Goldfarb DS
Aging (Albany NY); 2017 Jan; 9(1):68-97. PubMed ID: 28077781
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
Sasanuma H; Tsuda M; Morimoto S; Saha LK; Rahman MM; Kiyooka Y; Fujiike H; Cherniack AD; Itou J; Callen Moreu E; Toi M; Nakada S; Tanaka H; Tsutsui K; Yamada S; Nussenzweig A; Takeda S
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10642-E10651. PubMed ID: 30352856
[TBL] [Abstract][Full Text] [Related]
36. The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
Xiao H; Goodrich DW
Oncogene; 2005 Dec; 24(55):8105-13. PubMed ID: 16091739
[TBL] [Abstract][Full Text] [Related]
37. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
[TBL] [Abstract][Full Text] [Related]
38. A flow cytometry-based method for a high-throughput analysis of drug-stabilized topoisomerase II cleavage complexes in human cells.
de Campos-Nebel M; Palmitelli M; González-Cid M
Cytometry A; 2016 Sep; 89(9):852-60. PubMed ID: 27517472
[TBL] [Abstract][Full Text] [Related]
39. TDP2 suppresses chromosomal translocations induced by DNA topoisomerase II during gene transcription.
Gómez-Herreros F; Zagnoli-Vieira G; Ntai I; Martínez-Macías MI; Anderson RM; Herrero-Ruíz A; Caldecott KW
Nat Commun; 2017 Aug; 8(1):233. PubMed ID: 28794467
[TBL] [Abstract][Full Text] [Related]
40. DNA damage-induced activation of ATM promotes β-TRCP-mediated ARID1A ubiquitination and destruction in gastric cancer cells.
Jiang ZH; Peng T; Qian HL; Lu CD; Qiu F; Zhang SZ
Cancer Cell Int; 2019; 19():162. PubMed ID: 31210753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
